In the FIGARO-DKD and FIDELIO-DKD exploratory analyses of adult patients with CKD associated with T2D
*Remained stable for the duration of the trials.1
KERENDIA is indicated to reduce the
risk of sustained eGFR decline, end-stage kidney disease, cardiovascular death, non-fatal myocardial infarction, and hospitalization for heart failure in adult patients with chronic kidney disease (CKD) associated with type 2 diabetes (T2D)
Measure serum potassium periodically during treatment with KERENDIA and adjust dose accordingly. More frequent monitoring may be necessary for patients at risk for hyperkalemia, including those on concomitant medications that impair potassium excretion or increase serum potassium
Please read the Prescribing Information for KERENDIA.
References: 1. KERENDIA (finerenone) [prescribing information]. Whippany, NJ: Bayer HealthCare Pharmaceuticals, Inc.; September 2022. doi:10.1056/NEJMoa2025845. 2. American Diabetes Association® Professional Practice Committee; Draznin B, et al. Diabetes Care. 2022;45(suppl 1):S144-S184.